药物基因组学、药代动力学和循环蛋白作为优化癌症患者贝伐单抗治疗的生物标志物：综述
Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review.
作者信息
Papachristos Apostolos, Sivolapenko Gregory B
机构信息
Laboratory of Pharmacokinetics, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece.
出版信息
J Pers Med. 2020 Aug 4;10(3):79. doi: 10.3390/jpm10030079.
Abstract
Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor angiogenesis. Bevacizumab is approved for the treatment of various cancer, including metastatic colorectal cancer (mCRC), ovarian cancer, lung cancer, and others. Thus, it is widely used in oncology, but contrary to other therapeutic classes, there is still a lack of validating predictive factors for treatment outcomes with these agents. In recent years, the research for factors predictive of anti-VEGF treatments and especially bevacizumab response has been one of the most competitive translational research fields. Herein, we review and present the available literature of the clinical use of biomarkers, pharmacogenomics (PG), and therapeutic drug monitoring (TDM) approaches that can be used for the optimization of bevacizumab use in the era of precision medicine.
摘要
贝伐单抗是一种靶向血管内皮生长因子A（VEGF-A）并抑制肿瘤血管生成的单克隆抗体。贝伐单抗被批准用于治疗多种癌症，包括转移性结直肠癌（mCRC）、卵巢癌、肺癌等。因此，它在肿瘤学中被广泛应用，但与其他治疗类别不同的是，目前仍缺乏用于验证这些药物治疗效果的预测因素。近年来，对抗VEGF治疗尤其是贝伐单抗反应的预测因素研究一直是最具竞争力的转化研究领域之一。在此，我们回顾并介绍了生物标志物、药物基因组学（PG）和治疗药物监测（TDM）方法在临床应用中的现有文献，这些方法可用于在精准医学时代优化贝伐单抗的使用。
相似文献
1
Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review.药物基因组学、药代动力学和循环蛋白作为优化癌症患者贝伐单抗治疗的生物标志物：综述
J Pers Med. 2020 Aug 4;10(3):79. doi: 10.3390/jpm10030079.
2
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.转移性结直肠癌（mCRC）中抗血管生成治疗的生物标志物：原始数据及文献综述
Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30.
3
and Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.基因多态性可预测转移性结直肠癌一线贝伐珠单抗治疗的临床结局。
Int J Mol Sci. 2019 Nov 18;20(22):5791. doi: 10.3390/ijms20225791.
4
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.治疗期间VEGF表达降低可能是转移性结直肠癌患者对一线FOLFIRI联合贝伐单抗治疗反应性的一个预测指标。
Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015.
5
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.靶向血管内皮生长因子的单克隆抗体：癌症治疗的现状与未来挑战
BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.
6
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.单克隆抗体在转移性结直肠癌治疗中的应用：综述。
Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012.
7
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.贝伐珠单抗（安维汀®）在癌症治疗中的应用：15 年临床经验回顾及未来展望。
Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. Epub 2020 Mar 26.
8
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.促血管生成肿瘤蛋白作为贝伐珠单抗治疗转移性结直肠癌的潜在预测或预后生物标志物。
Int J Cancer. 2014 Aug 1;135(3):731-41. doi: 10.1002/ijc.28698. Epub 2014 Jan 24.
9
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).一项关于贝伐单抗与FOLFOX/OXXEL联合用药优化治疗转移性结直肠癌患者的随机3期研究——OBELICS（化疗方案中贝伐单抗给药方案的优化）
BMC Cancer. 2016 Feb 8;16:69. doi: 10.1186/s12885-016-2102-y.
10
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.贝伐单抗：一种用于治疗实体恶性肿瘤的血管生成抑制剂。
Clin Ther. 2006 Nov;28(11):1779-802. doi: 10.1016/j.clinthera.2006.11.015.
引用本文的文献
1
Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies.贝伐单抗在卵巢癌治疗中的应用：当前进展、临床挑战及新兴策略
Front Bioeng Biotechnol. 2025 May 15;13:1589841. doi: 10.3389/fbioe.2025.1589841. eCollection 2025.
2
Chick Chorioallantoic Membrane as an in vivo Model for the Study of Angiogenesis and Lymphangiogenesis.鸡胚绒毛尿囊膜作为研究血管生成和淋巴管生成的体内模型。
J Vasc Res. 2025;62(2):109-120. doi: 10.1159/000542875. Epub 2024 Dec 20.
3
Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.胶质瘤试验中的抗血管生成排除规则：历史视角及对未来试验设计的指导
Neurooncol Adv. 2024 Mar 15;6(1):vdae039. doi: 10.1093/noajnl/vdae039. eCollection 2024 Jan-Dec.
4
Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?FGFR 抑制剂试验中的患者选择方法——殊途同归？
Cells. 2022 Oct 10;11(19):3180. doi: 10.3390/cells11193180.
5
Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.基于接受贝伐珠单抗治疗的真实世界小样本患者开发的生存数据模型的机器学习引导协变量选择。
CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1328-1340. doi: 10.1002/psp4.12848. Epub 2022 Aug 4.
6
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.含贝伐珠单抗方案治疗的 1520 例癌症患者生存的全基因组关联研究。
Int J Cancer. 2022 Jan 15;150(2):279-289. doi: 10.1002/ijc.33810. Epub 2021 Oct 5.
7
Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.用于治疗缺氧肿瘤的实验性碳酸酐酶抑制剂
J Exp Pharmacol. 2020 Dec 15;12:603-617. doi: 10.2147/JEP.S265620. eCollection 2020.
本文引用的文献
1
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.基于遗传药理学的贝伐珠单抗治疗转移性结直肠癌的模型优化。
Int J Mol Sci. 2020 May 26;21(11):3753. doi: 10.3390/ijms21113753.
2
Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.贝伐珠单抗暴露与转移性结直肠癌患者生存的相关性。
Oncologist. 2020 Oct;25(10):853-858. doi: 10.1634/theoncologist.2019-0835. Epub 2020 Apr 28.
3
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.卡铂和紫杉醇联合或不联合贝伐珠单抗治疗上皮性卵巢癌患者的预测性基于血液的生物标志物：来自 GOG-0218 的结果。
Clin Cancer Res. 2020 Mar 15;26(6):1288-1296. doi: 10.1158/1078-0432.CCR-19-0226. Epub 2020 Jan 9.
4
and Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.基因多态性可预测转移性结直肠癌一线贝伐珠单抗治疗的临床结局。
Int J Mol Sci. 2019 Nov 18;20(22):5791. doi: 10.3390/ijms20225791.
5
Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.贝伐单抗登月计划：最新卵巢癌任务的一项重要成果。
J Clin Oncol. 2020 Jan 10;38(2):171-172. doi: 10.1200/JCO.19.01912. Epub 2019 Nov 7.
6
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.总血管内皮生长因子及未与贝伐单抗结合的血管内皮生长因子作为结直肠癌中基于贝伐单抗化疗的潜在预测因素。
World J Gastroenterol. 2016 Jul 21;22(27):6287-95. doi: 10.3748/wjg.v22.i27.6287.
7
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.贝伐单抗的药代动力学影响转移性结直肠癌患者的总生存期和无进展生存期。
Clin Pharmacokinet. 2016 Nov;55(11):1381-1394. doi: 10.1007/s40262-016-0406-3.
8
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.TWIST1基因多态性可预测接受一线贝伐单抗联合奥沙利铂化疗的转移性结直肠癌患者的生存情况。
Mol Cancer Ther. 2016 Jun;15(6):1405-11. doi: 10.1158/1535-7163.MCT-15-0751. Epub 2016 Mar 16.
9
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.白细胞介素6基因变异对接受贝伐单抗化疗的转移性结直肠癌患者的预后影响
Clin Cancer Res. 2016 Jul 1;22(13):3218-26. doi: 10.1158/1078-0432.CCR-15-2422. Epub 2016 Feb 2.
10
High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.基线时高VEGF-A水平预示着贝伐单抗为基础的化疗对转移性结直肠癌的治疗效果不佳：一项荟萃分析。
Panminerva Med. 2016 Mar;58(1):48-58. Epub 2016 Jan 13.
Zotero 插件